Holly E. Holmes

1.1k total citations
28 papers, 579 citations indexed

About

Holly E. Holmes is a scholar working on Oncology, Physiology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Holly E. Holmes has authored 28 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Physiology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Holly E. Holmes's work include Alzheimer's disease research and treatments (9 papers), Advanced Neuroimaging Techniques and Applications (8 papers) and CAR-T cell therapy research (6 papers). Holly E. Holmes is often cited by papers focused on Alzheimer's disease research and treatments (9 papers), Advanced Neuroimaging Techniques and Applications (8 papers) and CAR-T cell therapy research (6 papers). Holly E. Holmes collaborates with scholars based in United States, United Kingdom and France. Holly E. Holmes's co-authors include Mark F. Lythgoe, Jack A. Wells, Elizabeth Fisher, Emily C. Collins, Ozama Ismail, Ross A. Johnson, Bernard Siow, Ian F. Harrison, Tracey K. Murray and Michael J. O’Neill and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and NeuroImage.

In The Last Decade

Holly E. Holmes

27 papers receiving 575 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Holly E. Holmes United States 13 265 107 84 76 71 28 579
Gen Yan China 17 174 0.7× 46 0.4× 46 0.5× 53 0.7× 116 1.6× 49 639
P Chiarini Italy 14 183 0.7× 93 0.9× 67 0.8× 189 2.5× 116 1.6× 28 615
Stefan Vollmar Germany 15 397 1.5× 92 0.9× 75 0.9× 113 1.5× 154 2.2× 21 909
Hugh Pemberton United Kingdom 12 142 0.5× 226 2.1× 109 1.3× 126 1.7× 93 1.3× 22 611
Xueying Ling China 14 330 1.2× 32 0.3× 118 1.4× 61 0.8× 30 0.4× 38 543
Renaud Maroy France 12 214 0.8× 159 1.5× 91 1.1× 55 0.7× 167 2.4× 16 649
M Wallner-Blazek Austria 17 230 0.9× 102 1.0× 92 1.1× 186 2.4× 163 2.3× 20 969
Stig P. Cramer Denmark 10 183 0.7× 99 0.9× 32 0.4× 89 1.2× 64 0.9× 21 681
V. Acuff United States 13 236 0.9× 75 0.7× 34 0.4× 127 1.7× 86 1.2× 17 585
Guy Poloni Italy 14 224 0.8× 86 0.8× 41 0.5× 244 3.2× 107 1.5× 24 702

Countries citing papers authored by Holly E. Holmes

Since Specialization
Citations

This map shows the geographic impact of Holly E. Holmes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holly E. Holmes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holly E. Holmes more than expected).

Fields of papers citing papers by Holly E. Holmes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holly E. Holmes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holly E. Holmes. The network helps show where Holly E. Holmes may publish in the future.

Co-authorship network of co-authors of Holly E. Holmes

This figure shows the co-authorship network connecting the top 25 collaborators of Holly E. Holmes. A scholar is included among the top collaborators of Holly E. Holmes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holly E. Holmes. Holly E. Holmes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Casalena, Gabriella, et al.. (2022). Gene expression profiles in sporadic ALS fibroblasts define disease subtypes and the metabolic effects of the investigational drug EH301. Human Molecular Genetics. 31(20). 3458–3477. 8 indexed citations
3.
Olszewski, Adam J., Abraham Avigdor, Sunil Babu, et al.. (2021). MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES. Hematological Oncology. 39(S2). 4 indexed citations
4.
Holmes, Holly E., et al.. (2020). Safety Assessment of High-Purity, Synthetic Nicotinamide Riboside (NR-E) in a 90-Day Repeated Dose Oral Toxicity Study, With a 28-Day Recovery Arm. International Journal of Toxicology. 39(4). 307–320. 9 indexed citations
5.
6.
7.
Budde, Lihua E., Sunil Babu, Izidore S. Lossos, et al.. (2019). ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMA (NHL). Hematological Oncology. 37(S2). 564–566. 1 indexed citations
8.
Clayton, Emma L., Renzo Mancuso, Troels T. Nielsen, et al.. (2017). Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation. Human Molecular Genetics. 26(5). ddx003–ddx003. 23 indexed citations
9.
O'Callaghan, J.M., Holly E. Holmes, Nick Powell, et al.. (2017). Tissue magnetic susceptibility mapping as a marker of tau pathology in Alzheimer's disease. NeuroImage. 159. 334–345. 43 indexed citations
10.
Holmes, Holly E., Nick Powell, Da Ma, et al.. (2017). Comparison of In Vivo and Ex Vivo MRI for the Detection of Structural Abnormalities in a Mouse Model of Tauopathy. Frontiers in Neuroinformatics. 11. 20–20. 39 indexed citations
11.
Colgan, Niall, Balaji Ganeshan, Ian F. Harrison, et al.. (2017). In Vivo Imaging of Tau Pathology Using Magnetic Resonance Imaging Textural Analysis. Frontiers in Neuroscience. 11. 599–599. 8 indexed citations
12.
Shah, Bijal, Wendy Stock, William G. Wierda, et al.. (2017). Preliminary results of novel safety interventions in adult patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in the ZUMA-3 Trial. Annals of Oncology. 28. v360–v360. 1 indexed citations
13.
Powell, Nick, Marc Modat, M. Jorge Cardoso, et al.. (2016). Fully-Automated μMRI Morphometric Phenotyping of the Tc1 Mouse Model of Down Syndrome. PLoS ONE. 11(9). e0162974–e0162974. 13 indexed citations
14.
Colgan, Niall, Bernard Siow, John M. O’Callaghan, et al.. (2015). Application of neurite orientation dispersion and density imaging (NODDI) to a tau pathology model of Alzheimer's disease. NeuroImage. 125. 739–744. 154 indexed citations
15.
Ismail, Ozama, Ian F. Harrison, Holly E. Holmes, et al.. (2015). P1‐029: Imaging the efficacy of microtubule stabilizing agent epothilone d in the rtg4510 mouse model of tauopathy. Alzheimer s & Dementia. 11(7S_Part_7). 2 indexed citations
16.
Escalante, Carmen P., Christina Meyers, James M. Reuben, et al.. (2014). A Randomized, Double-blind, 2-Period, Placebo-Controlled Crossover Trial of a Sustained-Release Methylphenidate in the Treatment of Fatigue in Cancer Patients. The Cancer Journal. 20(1). 8–14. 61 indexed citations
17.
Ma, Da, M. Jorge Cardoso, Marc Modat, et al.. (2014). Automatic Structural Parcellation of Mouse Brain MRI Using Multi-Atlas Label Fusion. PLoS ONE. 9(1). e86576–e86576. 52 indexed citations
18.
O’Callaghan, James M., Jack A. Wells, Simon Richardson, et al.. (2014). Is Your System Calibrated? MRI Gradient System Calibration for Pre-Clinical, High-Resolution Imaging. PLoS ONE. 9(5). e96568–e96568. 25 indexed citations
19.
Agura, E.D., R.B. Berryman, Breanna Cooper, et al.. (2007). Phase II study of clofarabine and cytosine arabinoside in adult patients with relapsed AML and in elderly patients with untreated AML who are at high risk of anthracycline toxicity. Journal of Clinical Oncology. 25(18_suppl). 7064–7064. 2 indexed citations
20.
Holmes, Holly E., et al.. (1989). Osteoradionecrosis: its pathophysiology and treatment. A review of new concepts.. PubMed. 79(5). 17–23. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gen Yan Breakdown of academic impact, for papers by P Chiarini Breakdown of academic impact, for papers by Stefan Vollmar Breakdown of academic impact, for papers by Hugh Pemberton Breakdown of academic impact, for papers by Xueying Ling Breakdown of academic impact, for papers by Renaud Maroy Breakdown of academic impact, for papers by M Wallner-Blazek Breakdown of academic impact, for papers by Stig P. Cramer Breakdown of academic impact, for papers by V. Acuff Breakdown of academic impact, for papers by Guy Poloni
Rankless by CCL
2026